FDA expands pirtobrutinib into first-line CLL/SLL for adults without 17p deletion, delivering major PFS gains versus bendamustine-rituximab.
Related to this article
The oral azacitidine/cedazuridine combination was compared with subcutaneous azacitidine in the phase 3 portion of the AZTOUND trial.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Daniel Heng, MD, on How Belzutifan/Lenvatinib Fills an Unmet Need After Immunotherapy in RCC
2
Extended Survival Raises New Questions on Imaging and Treatment Intensification in ROS1+ NSCLC
3
What Stood Out at IMS 2026? 5 Myeloma Experts Weigh In
4
Telehealth May Offer a Path to More Equitable Myeloma Transplant Access
5